Search

Your search keyword '"Immunotherapy -- Technology application"' showing total 250 results
Start Over Descriptor "Immunotherapy -- Technology application"
250 results on '"Immunotherapy -- Technology application"'

1. Ainos advances innocations with AI Nose, VELDONA technologies

Subjects
Immunotherapy -- Technology application, Biological response modifiers -- Technology application, Occupational health and safety -- Technology application, Technology application, Business, News, opinion and commentary
Abstract

Ainos continues to push the boundaries of global smart healthcare and immunotherapy innovation. The company said, 'With its AI Nose and VELDONA low-dose oral interferon technologies, Ainos is not only [...]

Published
2024

2. Halozyme Announces argenx Received Approval in Japan for VYVDURA® efgartigimod alfa and hyaluronidase-qvfc Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis

Subjects
Drugs -- Vehicles, Immunotherapy -- Technology application, Myasthenia gravis -- Technology application, Drug delivery systems -- Technology application, Physical fitness -- Technology application, Technology application, Health
Abstract

2024 FEB 3 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ('Halozyme') announced that argenx received approval from [...]

Published
2024

3. Patent Application Titled 'Labeling Of Antibodies' Published Online (USPTO 20240325575)

Subjects
Biological products -- Technology application -- Intellectual property, Viral antibodies -- Technology application, Immunotherapy -- Technology application, Antibodies -- Technology application, Technology application, Health
Abstract

2024 OCT 23 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by [...]

Published
2024

4. University of Warsaw Researcher Details Research in Drugs and Therapies (Trinucleotide cap analogs with triphosphate chain modifications: synthesis, properties, and evaluation as mRNA capping reagents)

Subjects
Immunotherapy -- Technology application, Messenger RNA -- Technology application, Drugs -- Technology application, Technology application, Health
Abstract

2024 SEP 25 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on drugs and therapies. According to news reporting from Warsaw, Poland, [...]

Published
2024

5. Akoya Biosciences to showcase spatial biology 2.0 solutions

Subjects
Immunotherapy -- Technology application, Technology application, Business, News, opinion and commentary
Abstract

Akoya Biosciences will be showcasing its latest Spatial Biology 2.0 solutions and ultrahigh-plex spatial phenotyping data at the Society for Immunotherapy of Cancer 38th Annual Meeting, being held in San [...]

Published
2023

6. CDR-Life to Present Tumor Targeting Capabilities of M-gager(R) Platform at the TCR-Based Therapies for Solid Tumors Summit

Subjects
MHC antibodies -- Technology application, T cells -- Technology application, Tumors -- Technology application, Immunotherapy -- Technology application, Tumor antigens -- Technology application, Technology application, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development [...]

Published
2024

7. IMUNON Reports 2023 Financial Results and Provides Business Update

Subjects
Immunotherapy -- Technology application, Antigens -- Technology application, Vaccines -- Technology application, Ovarian cancer -- Technology application, Technology application, Company earnings/profit, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the year ended December 31, 2023. [...]

Published
2024

8. IMUNON to Hold 2023 Financial Results & Business Update Conference Call on Thursday, March 28, 2024

Subjects
Immunotherapy -- Technology application, Vaccines -- Technology application, Ovarian cancer -- Technology application, Technology application, General interest, News, opinion and commentary
Abstract

LAWRENCEVILLE: IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 10:00 a.m. ET [...]

Published
2024

9. New Gold Nanoparticles Study Findings Have Been Reported from Donghua University (Diselenide-crosslinked Nanogels Laden With Gold Nanoparticles and Methotrexate for Immunomodulation-enhanced Chemotherapy and Computed Tomography Imaging of Tumors)

Subjects
Tumors -- Diagnosis -- Care and treatment, Gold -- Usage, Chemotherapy -- Technology application, CT imaging -- Usage, Cancer -- Chemotherapy, Drug delivery systems -- Research, Drugs -- Vehicles, Colloids in medicine -- Usage -- Chemical properties, Nanoparticles -- Usage, Materials research, Immunotherapy -- Technology application, Methotrexate -- Dosage and administration, Selenium compounds -- Usage, Technology application, Health
Abstract

2023 JUL 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Nanotechnology - Gold Nanoparticles. According to news [...]

Published
2023

10. CDR-Life Announces FDA Clearance of IND Application for CDR404 for Treatment of Solid Tumors

Subjects
United States. Food and Drug Administration -- Technology application, Tumors -- Drug therapy, Immunotherapy -- Technology application, Lung cancer, Non-small cell -- Drug therapy, Tumor antigens -- Technology application, Technology application, Business, international, Law
Abstract

(GlobeNewswire) - CDR-Life Inc. today announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for CDR404, its lead program in development [...]

Published
2024

11. CDR-Life Announces FDA Clearance of IND Application for CDR404 for Treatment of Solid Tumors

Subjects
United States. Food and Drug Administration -- Technology application, T cells -- Technology application, Tumors -- Drug therapy, Immunotherapy -- Technology application, Tumor antigens -- Technology application, Technology application, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- First-of-its-kind, antibody-based, bivalent and bispecific MAGE-A4 T-cell engager ZURICH, Switzerland, Jan. 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced the clearance of an Investigational [...]

Published
2024

12. ClearNote Health Announces New Proprietary Approach for Predicting Immunotherapy Treatment Response in Non-Small Cell Lung Cancer Using Only Blood

Subjects
Medical research -- Technology application, Medicine, Experimental -- Technology application, Cancer -- Diagnosis -- Care and treatment, Lung cancer, Small cell -- Prognosis, Immunotherapy -- Technology application, Lung cancer, Non-small cell -- Prognosis, Technology application, Business, Business, international
Abstract

New data published in The Journal for ImmunoTherapy of Cancer show ClearNote Health's epigenomic platform may provide a novel tissue-free, liquid biopsy-based approach for prediction and monitoring of immunotherapy response [...]

Published
2024

13. AIVITA Biomedical CEO Dr. Hans Keirstead to Present at Biotech Showcase 2024

Subjects
Stem cells -- Technology application, Biotechnology -- Technology application, Biotechnology industry -- Technology application, Immunotherapy -- Technology application, Chief executive officers -- Technology application, Cancer vaccines -- Technology application, Technology application, Business, News, opinion and commentary
Abstract

IRVINE, Calif., Jan. 5, 2024 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chief executive officer Hans S. Keirstead, Ph.D. will [...]

Published
2024

14. Patent Issued for Plasmid system (USPTO 11965173)

Subjects
T cells -- Technology application, Immunotherapy -- Technology application, Technology application, Health
Abstract

2024 MAY 15 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the [...]

Published
2024

15. Promontory Therapeutics gets US patent for therapeutic applications of PT-112 as an immuno-modulatory agent

Subjects
Cell death -- Technology application, Immunotherapy -- Technology application, Technology application, Pharmaceuticals and cosmetics industries
Abstract

Byline: New York Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, announced the United States Patent and Trademark Office has issued a patent covering [...]

Published
2022

17. PRodrug technology for Immunotherapy-priming via patient-friendly at-home MEtronomic dosing

Subjects
Immunotherapy -- Technology application, Chemotherapy -- Technology application, Cancer -- Chemotherapy, Technology application, Business, international, European Union -- Technology application
Abstract

Prodrug Technology For Immunotherapy-Priming Via Patient-Friendly At-Home Metronomic Dosing Objective Immunotherapy holds great promise for curative cancer treatment. While immune checkpoint inhibitors can induce complete and long-term cures, the percentage [...]

Published
2023

18. HDT Bio to Present Novel Vaccine Technologies for Cancer Immunoprevention at SITC 2023 Annual Meeting

Subjects
Cancer -- Prevention -- Care and treatment, Immunotherapy -- Technology application, Vaccines -- Technology application, Technology application, Business, News, opinion and commentary
Abstract

SEATTLE, Oct. 31, 2023 /PRNewswire/ -- HDT Bio Corp., a clinical-stage private company developing advanced RNA products to treat and prevent infectious diseases and cancer, today announced that Dr. Steven [...]

Published
2023

19. NEC OncoImmunity publishes research using its neoantigen prediction technology showing improved outcome in sarcoma patients treated with cancer immunotherapy

Subjects
Oncology, Experimental -- Technology application, Sarcoma -- Drug therapy -- Development and progression -- Patient outcomes, Cancer patients -- Drug therapy -- Patient outcomes, Immunotherapy -- Technology application, Cancer -- Care and treatment -- Development and progression -- Patient outcomes -- Drug therapy -- Research, Tumor antigens -- Technology application, Technology application, General interest, News, opinion and commentary
Abstract

OSLO: NEC OncoImmunity AS has issued the following news release: NEC OncoImmunity AS (NOI) today announced it has published a study that describes the use of its artificial intelligence (AI) [...]

Published
2023

20. NEC OncoImmunity publishes research using its neoantigen prediction technology showing improved outcome in sarcoma patients treated with cancer immunotherapy

Subjects
Oncology, Experimental -- Technology application, Sarcoma -- Drug therapy -- Development and progression -- Patient outcomes, Cancer patients -- Drug therapy -- Patient outcomes, Immunotherapy -- Technology application, Cancer -- Care and treatment -- Development and progression -- Patient outcomes -- Drug therapy -- Research, Tumor antigens -- Technology application, Technology application, News, opinion and commentary
Abstract

OSLO, Norway--(BUSINESS WIRE)--Oct 17, 2023-- NEC OncoImmunity AS (NOI) today announced it has published a study that describes the use of its artificial intelligence (AI) based neoantigen prediction technology to [...]

Published
2023

21. NEC OncoImmunity publishes research using its neoantigen prediction technology showing improved outcome in sarcoma patients treated with cancer immunotherapy

Subjects
Oncology, Experimental -- Technology application, Sarcoma -- Drug therapy -- Development and progression -- Patient outcomes, Cancer patients -- Drug therapy -- Patient outcomes, Immunotherapy -- Technology application, Cancer -- Care and treatment -- Development and progression -- Patient outcomes -- Drug therapy -- Research, Tumor antigens -- Technology application, Technology application, Business, Business, international
Abstract

OSLO, Norway -- NEC OncoImmunity AS (NOI) today announced it has published a study that describes the use of its artificial intelligence (AI) based neoantigen prediction technology to demonstrate that [...]

Published
2023

22. iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics

Subjects
T cells -- Technology application, Viral antibodies -- Technology application, Immunotherapy -- Technology application, Machine learning -- Technology application, Festivals -- Technology application, Antibodies -- Technology application, Technology application, Banking, finance and accounting industries, Business
Abstract

- VP of Platform Technologies, Matt Greving, to present data on enhancing T-cell engagers using machine-learning guided epitope steering and mammalian display antibody libraries - BRYAN, Texas and SAN DIEGO, [...]

Published
2023

23. Studies from Suzhou University of Science and Technology Update Current Data on Nanocomposites (Magnetic Two-dimensional Nanocomposites for Multimodal Antitumor Therapy: a Recent Review)

Subjects
Antineoplastic agents -- Technology application, Immunotherapy -- Technology application, Biomedical engineering -- Technology application, Antimitotic agents -- Technology application, Technology application, Health
Abstract

2024 FEB 28 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on Nanotechnology - Nanocomposites. According to news originating from Jiangsu, People's [...]

Published
2024

24. Data on Nanoprobes Described by Researchers at Southeast University (Acidic Tumor Microenvironment-activated Mri Nanoprobes for Modulation and Visualization of Anti-pd-l1 Immunotherapy)

Subjects
Tumors -- Technology application, Immunotherapy -- Technology application, Imaging systems -- Technology application, Imaging technology, Technology application, Health
Abstract

2024 FEB 28 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on Nanotechnology - Nanoprobes have been published. According to news reporting from [...]

Published
2024

25. Researchers Submit Patent Application, 'Multivalent Meditopes, Meditope-Binding Antibodies And Uses Thereof', for Approval (USPTO 20230391887)

Subjects
Biological products -- Technology application -- Intellectual property, Antineoplastic agents -- Technology application -- Intellectual property, Antiviral agents -- Intellectual property -- Technology application, Immunotherapy -- Technology application, Amino acids -- Technology application -- Intellectual property, Monoclonal antibodies -- Technology application, Antimitotic agents -- Technology application -- Intellectual property, Technology application, Health
Abstract

2023 DEC 27 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- From Washington, D.C., NewsRx journalists report that a patent application by the inventor WILLIAMS, John [...]

Published
2023

26. Findings from National Institute of Advanced Industrial Science and Technology (NIAIST) Broaden Understanding of Nanoparticles (Protein's Protein Corona: Nanoscale Size Evolution of Human Immunoglobulin G Aggregates Induced By Serum Albumin)

Subjects
Nanoparticles -- Chemical properties -- Health aspects, Immunotherapy -- Technology application, Protein research, Immunoglobulin G -- Physiological aspects, Technology application, Health
Abstract

2022 AUG 27 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Nanotechnology - Nanoparticles have been presented. According to news [...]

Published
2022

27. Reports on Methicillin-Resistant Staphylococcus aureus Findings from Shanghai Jiao Tong University Provide New Insights (Photosensitizer Nanodot Eliciting Immunogenicity for Photo-immunologic Therapy of Postoperative Methicillin-resistant ...)

Subjects
Surgical wound infections -- Drug therapy, Nanoparticles -- Usage -- Health aspects, Phototherapy -- Technology application, Immunotherapy -- Technology application, Staphylococcus aureus infections -- Drug therapy, Technology application, Health
Abstract

2022 MAR 12 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on Drugs and Therapies - Methicillin-Resistant Staphylococcus aureus is the [...]

Published
2022

28. A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US

Subjects
T cells -- Technology application, Stem cells -- Technology application -- Transplantation, Immunotherapy -- Technology application, Technology application, Business, News, opinion and commentary
Abstract

SINGAPORE, July 6, 2023 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3912817-1&h=3495914835&u=https%3A%2F%2Fw2.cytomed.sg%2F&a=CytoMed+Therapeutics+Limited(NASDAQ: GDTC) ('CytoMed' or 'Company'), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor cell-based immunotherapies for the treatment [...]

Published
2023

29. DBV Technologies to Participate in Upcoming Investor Conference

Subjects
Immunotherapy -- Technology application, Food allergy -- Technology application, Technology application, Banking, finance and accounting industries, Business
Abstract

Montrouge, France, June 06, 2023 DB V Technologies to Participate in Upcoming Investor Conference Investor Contact Katie MatthewsDBV Technologies+1 857-529-2563https://www.globenewswire.com/Tracker?data=ujBVNw5iU-rqu5g2i6JvoQGM49bHsXvXRuE8GhJIsMIIvm9g1fsQPJLOCk2y2WSgvg_9gTOhk3K7GAAuj-da7JALz_0M3jouXSK6JZpU33egQaM8SqqQbWT3JBku_mUHA-4Bx16zSmV_2Eyj1b_xOg== A replay will also be available on DBV Technologies' website [...]

Published
2023

30. AESOP Technology Announces Collaboration with AstraZeneca Taiwan on Medigator: Advancing Shared Decision-Making in Precision Medicine

Subjects
Immunotherapy -- Technology application, Patient education -- Technology application, Technology application, Business, News, opinion and commentary
Abstract

CHICAGO, June 2, 2023 /PRNewswire/ -- https://www.aesoptek.com/about.html, in collaboration with AstraZeneca Taiwan, has unveiled https://www.aesoptek.com/medigator.html, an innovative AI software designed to manage immune-related adverse events (irAEs) and enhance the effectiveness [...]

Published
2023

31. Biotech role in future medicines

Subjects
Pfizer Inc. -- Technology application, Biotechnology -- Technology application, Biotechnology industry -- Technology application, Immunotherapy -- Technology application, Drugs -- Technology application, Vaccines -- Technology application, Pharmaceutical industry -- Technology application, Technology application, News, opinion and commentary
Abstract

The recent visit to Belgium by President William Ruto has fuelled biotechnology (biotech) investments and knowledge transfer to Kenya, especially in medicine.Biotech involves using living organisms or their products to [...]

Published
2023

32. DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

Subjects
Financial markets -- Technology application, Immunotherapy -- Technology application, Technology application, Company earnings/profit, Banking, finance and accounting industries, Business
Abstract

Montrouge, France, April 12, 2023 DBV Technologies Announces Results of its 202 3 Ordinary and Extraordinary General Meeting Shareholders A pprove d A ll P roposed R esolutions DBV Technologies [...]

Published
2023

33. AIVITA Biomedical Chief Medical Officer Dr. Robert Dillman to Deliver Keynote at World Immunotherapy Congress

Subjects
Sheraton San Diego Hotel & Marina -- Technology application, Immunotherapy -- Technology application, Cancer vaccines -- Technology application, Hotels and motels -- California -- United States, Technology application, General interest, News, opinion and commentary
Abstract

IRVINE: AIVITA Biomedical, Inc. has issued the following news release: AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that Chief Medical Officer Dr. Robert [...]

Published
2023

34. AIVITA Biomedical Chief Medical Officer Dr. Robert Dillman to Deliver Keynote at World Immunotherapy Congress

Subjects
Sheraton San Diego Hotel & Marina -- Technology application, Stem cells -- Technology application, Immunotherapy -- Technology application, Cancer vaccines -- Technology application, Hotels and motels -- California -- United States, Technology application, Business, News, opinion and commentary
Abstract

IRVINE, Calif., March 16, 2023 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that Chief Medical Officer Dr. Robert O. Dillman will [...]

Published
2023

35. DBV Technologies Update

Subjects
Silicon Valley Bank -- Technology application, Banking industry -- Technology application, Immunotherapy -- Technology application, Technology application, Banking industry, General interest, News, opinion and commentary
Abstract

New York: DBV Technologies S.A. has issued the following news release: DBV Technologies Update DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, informs [...]

Published
2023

36. DBV Technologies Update

Subjects
Silicon Valley Bank -- Technology application, Banking industry -- Technology application, Immunotherapy -- Technology application, Technology application, Banking industry, Banking, finance and accounting industries, Business
Abstract

Montrouge, France, March 13, 2023 DBV Technologies Update DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, informs its investors that it does not [...]

Published
2023

37. DBV Technologies Update

Subjects
Silicon Valley Bank -- Technology application, Banking industry -- Technology application, Immunotherapy -- Technology application, Technology application, Banking industry, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Montrouge, France, March 13, 2023 DBV Technologies Update DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, informs its [...]

Published
2023

38. Avalon GloboCare jointly filed US, International patent application for SLET

Subjects
Drugs -- Vehicles, Immunotherapy -- Technology application, Drug delivery systems -- Intellectual property -- Technology application, Technology application, Business, News, opinion and commentary
Abstract

Avalon GloboCare announced it has successfully co-developed a novel platform of S-layer coated emulsome technology, or SLET, for next-generation drug delivery and cellular immunotherapy, together with Professor Uwe Sleytr and [...]

Published
2021

39. Reports Summarize Phototherapy Study Results from Harbin Institute of Technology (Nickel Phosphide for Mri-guided Synergistic Photo-immunotherapy)

Subjects
Metastasis -- Technology application, Phototherapy -- Technology application, Immunotherapy -- Technology application, Technology application, Health
Abstract

2023 JUL 12 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Data detailed on Drugs and Therapies - Phototherapy have been presented. According to news reporting [...]

Published
2023

40. ABL Bio announces publication of preclinical data highlighting safety and anti-tumor efficacy of ABL503/TJ-L14B in JITC

Subjects
Tumors -- Drug therapy, Nervous system diseases -- Drug therapy, Viral antibodies -- Technology application, Immunotherapy -- Technology application, Antibodies -- Technology application, Technology application, Pharmaceuticals and cosmetics industries
Abstract

ABL Bio, Inc., a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced the publication of pre-clinical data highlighting the safety and anti-tumor efficacy of ABL503/TJ-L14B in [...]

Published
2021

41. Turn Biotechnologies to Present at Next Generation CAR & T Cell Therapies Conference on February 28

Subjects
T cells -- Technology application, Biotechnology -- Technology application, Biotechnology industry -- Technology application, Immunotherapy -- Technology application, Conferences and conventions -- Technology application, Epigenetic inheritance -- Technology application, Technology application, Business, News, opinion and commentary
Abstract

Presentation to show how ERA(TM)-treated T cells demonstrate improved cancer-killing capacity and promise to reduce cost of manufacturing immune therapy medicines MOUNTAIN VIEW, Calif., Feb. 28, 2023 /PRNewswire/ -- Turn [...]

Published
2023

42. Medigene Presents First Results for Automated Manufacturing of T Cell Receptor Engineered T Cells

Subjects
MediGene AG -- Technology application, T cells -- Technology application, Biotechnology industry -- Technology application, Immunotherapy -- Technology application, Technology application, Telecommunications industry
Abstract

(GlobeNewswire) - Medigene AG (Medigene, FSE: MDG1, Prime Standard) is an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Prof. Dr. [...]

Published
2023

43. Iaso Therapeutics Announces First Close in $1.25M Equity Series Seed Preferred Financing

Subjects
Immunotherapy -- Technology application, Antigens -- Technology application, Vaccines -- Technology application, Technology application, General interest, News, opinion and commentary, Michigan State University -- Officials and employees
Abstract

EAST LANSING: EAST LANSING has issued the following news release: Iaso Therapeutics, a Michigan State University startup developing novel technologies for next-generation vaccines, recently closed the first tranche of the [...]

Published
2023

44. Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV (enfortumab vedotin-ejfv) with KEYTRUDA (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Subjects
United States. Food and Drug Administration -- Technology application, Merck & Company Inc. -- Technology application, Astellas Pharma Inc. -- Technology application, Biopharmaceutics -- Technology application, Metastasis -- Technology application, Immunotherapy -- Technology application, Cancer -- Technology application, Technology application, Business, News, opinion and commentary, Padcev (Medication), Keytruda (Medication)
Abstract

-- This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting -- -- FDA granted the applications Priority [...]

Published
2022

45. Tiziana Life Sciences Announces Date of Annual General Meeting 2022

Subjects
Drugs -- Vehicles, Immunotherapy -- Technology application, Drug delivery systems -- Technology application, Technology application, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ('Tiziana' or the 'Company'), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, [...]

Published
2022

46. Pyxis Oncology Announces FDA Clearance of Two IND Applications

Subjects
United States. Food and Drug Administration -- Technology application, Biological products -- Product development, Immunotherapy -- Technology application, Clinical trials -- Technology application, Thyroid cancer -- Care and treatment, Technology application, Telecommunications industry
Abstract

(GlobeNewswire) - Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, announced today that it has received clearance for its two [...]

Published
2022

48. Vaccitech to Host KOL Webinar on the SNAPvax Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

Subjects
Communicable diseases -- Care and treatment, Autoimmunity -- Technology application, Immunotherapy -- Technology application, Vaccines -- Technology application, Autoimmune diseases -- Care and treatment, Technology application, General interest, News, opinion and commentary
Abstract

OXFORD: Vaccitech plc has issued the following press release: Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax Platform and [...]

Published
2022

49. Vaccitech to Host KOL Webinar on the SNAPvax,ao Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

Subjects
Communicable diseases -- Technology application, Autoimmunity -- Technology application, Immunotherapy -- Technology application, Vaccines -- Technology application, Autoimmune diseases -- Technology application, Technology application, Telecommunications industry
Abstract

(GlobeNewswire) - Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax Platform and application in tolerogenic immunotherapies for celiac disease [...]

Published
2022

50. Vaccitech to Host KOL Webinar on the SNAPvax(TM) Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

Subjects
Communicable diseases -- Care and treatment, Autoimmunity -- Technology application, Immunotherapy -- Technology application, Vaccines -- Technology application, Autoimmune diseases -- Care and treatment, Technology application, Banking, finance and accounting industries, Business
Abstract

OXFORD, United Kingdom, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax(TM) Platform and [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results